Ginkgo Bioworks Holdings (DNA) Other Non-Current Liabilities (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Other Non-Current Liabilities for 7 consecutive years, with $16.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 8.76% year-over-year to $16.4 million; the trailing twelve-month figure through Jun 2026 stood at $16.4 million (down 8.76% YoY), and the FY2025 full-year result was $22.9 million, up 38.01% from the prior year.
• Other Non-Current Liabilities declined to $16.4 million in Q2 2026 per DNA's latest filing, from $21.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $50.8 million in Q1 2022 and bottomed at $15.4 million in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $24.6 million across 5 years, with a median of $21.3 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities slumped 81.34% in 2022, then soared 40.84% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $31.2 million in 2022, then declined by 21.67% to $24.4 million in 2023, then plunged by 32.16% to $16.6 million in 2024, then jumped by 38.01% to $22.9 million in 2025, then fell by 28.43% to $16.4 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $16.4 million, $21.7 million, and $22.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.